𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pilot trial of concomitant chemotherapy with paclitaxel and split-course radiotherapy for very advanced squamous cell carcinoma of head and neck

✍ Scribed by Olavo Feher; Sandro J. Martins; Candice A. Lima; João V. Salvajoli; Andrew J. Simpson; Luiz P. Kowalski

Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
97 KB
Volume
24
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Purpose

The combination of chemotherapy and irradiation is considered the standard of care for the treatment of advanced squamous cell carcinoma of head and neck (SCCHN). Paclitaxel has shown a single‐agent activity in SCCHN. Besides, this drug is a promising radiosensitizer for some human solid tumors. This is a phase II trial to evaluate the feasibility, efficacy, and toxicity of paclitaxel administered concurrently with split‐course radiotherapy in advanced unresectable SCCHN.

Methods and Materials

Thirty‐one patients with advanced SCCHN were enrolled in this trial. Radiotherapy consisted of 66 to 70 Gy delivered over 8 to 10 weeks to the primary tumor and lymphatic drainage, with a fractionation scheme of 1.8 to 2 Gy/field/d. After the initial five patients were treated, a 1‐week treatment break was introduced. Paclitaxel was administered weekly in a 1‐hour intravenous infusion at a projected dosage of 45 mg/m^2^/wk.

Results

The complete and partial response rates, based on a 4‐week postradiation evaluation were 43.3% and 40%, respectively, with an overall response rate of 83.3%. Median survival was 49.4 weeks, and 1‐year survival was 48%. Freedom from local progression was 65.6% at 1 year. Thirty‐six percent and 20% of the patients are alive and disease free at 1 and 2 years, respectively. Grade 3/4 of acute toxicity consisted mostly of mucositis, cutaneous reaction, and weight loss.

Conclusions

Paclitaxel concurrent with radiotherapy seems to be active in squamous cell carcinoma of the head and neck. In the regimen selected for this trial, toxicity was significant and led to a prolongation of treatment time. © 2002 Wiley Periodicals, Inc. Head Neck 24: 228–235, 2002; DOI 10.1002/hed.10049

📜 SIMILAR VOLUMES

Evaluation of university of florida spli
Evaluation of university of florida split-course technique for various head and neck squamous cell carcinomas
✍ Rodney R. Million; Roland C. Zimmermann 📂 Article 📅 1975 🏛 John Wiley and Sons 🌐 English ⚖ 269 KB 👁 2 views

A retrospective evaluation was made of 260 patients with squamous carcinoma of various head and neck sites in order to determine the relative value of continuous vs. split-course irradiation techniques. There was no obvious difference in local control or survival in early-stage cases. The continuous

Pilot study of intraoperative chemothera
Pilot study of intraoperative chemotherapy with cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the head and neck
✍ Ozlem E. Tulunay; Ileana I. Enamorado; Omer Kucuk; Lance K. Heilbrun; Jose E. Ot 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 3 views

## Abstract ## Background. Intraoperative manipulation of the tumor during cancer surgery has long been recognized as a source of metastasis and contamination of the surgical wound during tumor removal. We explored the use of intraoperative chemotherapy to minimize the risk of tumor cell implantat

Paclitaxel, cisplatin, and 5-fluorouraci
Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck
✍ Maha Hussain; Shirish Gadgeel; Omer Kucuk; Wei Du; Walter Salwen; John Ensley 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 3 views

## BACKGROUND. The combination of cisplatin and 5-flurouracil (5-FU) is considered standard therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Paclitaxel has exhibited single-agent activity in patients with this disease. The authors conducted thi

Phase II study of induction chemotherapy
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck
✍ Dong M. Shin; Bonnie S. Glisson; Fadlo R. Khuri; Scott M. Lippman; Lawrence Gins 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 1 views

## Abstract ## BACKGROUND This Phase II trial was conducted to determine the response rate, particularly of the primary sites, tolerability, and toxicity of induction chemotherapy of paclitaxel, ifosfamide, and carboplatin for patients with previously untreated locally advanced squamous cell carci